Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2026
Reporting Period: Single event date (August 11, 2026)
The filing serves as a Regulation FD disclosure regarding a specific corporate development rather than a periodic financial report. The Company is a Delaware corporation with principal executive offices in New York, NY, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing is strictly informational regarding a regulatory milestone.
Material Changes
The material change disclosed is the completion of a multi-site Method Comparison Study for the Company's Intelligent Fingerprinting Drug Screening System. This study is a critical component supporting the Company's FDA 510(k) submission for U.S. market clearance specifically for the detection of the opiate codeine.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the study completion. The disclosure is qualified in its entirety by the full text of that press release.
Regulatory Status: The study underpins an ongoing FDA 510(k) submission process. No final clearance has been announced in this filing.
Risks and Contingencies: The filing notes that the information is furnished and not deemed "filed" for purposes of the Securities Exchange Act of 1934, nor incorporated by reference unless specifically identified. The success of the 510(k) submission remains contingent on FDA review following this study.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific study results and statistical data.
- Confirm the current status of the FDA 510(k) submission for codeine detection following this study completion.
- Review subsequent filings for any updates on the FDA review timeline or potential market launch dates.
- Check for any financial impact or capital requirements associated with the next phase of regulatory approval.